Mankind Pharma Ltd

Mankind Pharma Employee Stock Options

Mankind Pharma allotted 86,778 equity shares under its ESOP scheme. This increases the total paid-up share capital to 412,995,978 equity shares.

Mankind Pharma Employee Stock Options

Mankind Pharma allotted 86,778 equity shares worth ₹7.50 Crore under its 2022 ESOP Plan. The allotment increases the company's total paid-up equity share capital.

Value

₹7.50 Cr

Mankind Pharma Acquisition Worth ₹0.75 Cr

Mankind Pharma's subsidiary acquired the remaining 10% stake in Upakarma Ayurveda for ₹0.75 Crore. This transaction makes Upakarma a wholly-owned step-down subsidiary to improve operational efficiencies.

Value

₹0.75 Cr

Mankind Pharma Earnings Call: Key Takeaways

Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.

Mankind Pharma Management Change

Mankind Pharma announced the re-appointment of WTD Satish Kumar Sharma and the resignation of SMP Pramod Gokhale. These changes reflect standard corporate governance and leadership transitions.

Mankind Pharma Merger & Restructuring Worth ₹500 Cr

Mankind Pharma approved a ₹500 Crore investment in its subsidiary, Mankind Medicare, for capacity expansion. The capital will fund a new pharmaceutical manufacturing plant.

Value

₹500.0 Cr

Mankind Pharma Employee Stock Options

Mankind Pharma allotted 80,872 equity shares under its employee stock option scheme. Post-allotment, the company's paid-up share capital increased to 412,909,200 equity shares.

Mankind Pharma Results Update

Mankind Pharma reported FY26 revenue of ₹14,278 Crore, up 17% YoY. Q4FY26 adjusted EBITDA margins reached 27.1%, driven by strong domestic chronic and OTC growth.

Value

₹14,278 Cr

Mankind Pharma Earnings Call: Key Takeaways

Mankind Pharma reported ₹14,278 Cr FY26 revenue, focusing on increasing chronic share (39.9% in Q4) and super-specialty expansion via BSV acquisition.

Mankind Pharma Employee Stock Options

Mankind Pharma allotted 80,872 equity shares worth ₹7.51 Crore under its ESOP 2022 plan. This exercise increases the company's paid-up share capital to 41,29,09,200 shares.

Value

₹7.51 Cr

Mankind Pharma Q4 FY26 Results: Net Profit ₹559.4 Cr, Up 31.7% YoY

Mankind Pharma Ltd reported revenue from operations of ₹3,443 Cr (+11.8% YoY) and net profit of ₹559.4 Cr (+31.7% YoY) for Q4 FY26.

Key figure

Net profit ₹559.4 Cr · +31.7% YoY

Mankind Pharma Financial Results

Mankind Pharma approved its audited FY26 results, reporting consolidated annual revenue of ₹14,277.64 Crore. The Board also cleared a ₹500 Crore investment in its Medicare subsidiary.

Mankind Pharma Credit Rating

ICRA reaffirmed Mankind Pharma's AA+ ratings and assigned A1+ for ₹6,850 Crore in debt instruments. The stable outlook reflects the company's robust credit profile.

Value

₹6,850 Cr

Mankind Pharma Board Meeting Date

Mankind Pharma scheduled a board meeting on May 19, 2026. Directors will approve FY26 audited results and realignment of security cover for existing NCDs.

Mankind Pharma Other Announcement

Mankind Pharma Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. Issued by M/s Amit Gupta & Associates, the report confirms the company's adherence to SEBI regulations and statutory provisions. This filing is a routine regulatory requirement for listed entities in India.

Mankind Pharma Credit Rating

Mankind Pharma Limited has been assigned credit ratings by CARE Ratings Limited for ₹1,000 Crore in bank facilities. The long-term and short-term facilities received 'CARE AA+; Stable' and 'CARE A1+' ratings respectively. This assignment reflects the company's creditworthiness and stable financial outlook.

Value

₹1,000 Cr

Mankind Pharma Debt & Borrowing: ₹1,270 Cr

Mankind Pharma Ltd has completed the redemption of NCDs (INE634S07017) and paid total interest of ₹198.95 Crore across three NCD series on April 16, 2026. The total outflow for redemption and interest payments amounted to ₹1,448.95 Crore. This fulfills the company's scheduled debt obligations and reduces outstanding non-convertible debenture liabilities.

Value

₹1,270 Cr

Mankind Pharma Merger & Restructuring

Mankind Pharma Limited's Board has approved the winding-up of its Sri Lankan wholly owned subsidiary, Mankind Pharma Lanka (Private) Limited. The entity had no active operations and became unviable due to regulatory changes. This closure is not expected to materially impact the company's consolidated financials.

Mankind Pharma Debt & Borrowing: ₹5,000 Cr

Mankind Pharma Limited submitted a half-yearly statement for its listed privately placed debt securities ending March 31, 2026. The disclosure tracks three NCD series totalling ₹5,000 Crore in outstanding principal, with coupon rates between 7.97% and 7.99%.

Value

₹5,000 Cr